Top 3 Health Care Stocks You May Want To Dump This Quarter
Top 3 Health Care Stocks You May Want To Dump This Quarter
As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年7月30日，醫療保健行業的三隻股票可能會向將動量視爲交易決策關鍵標準的投資者發出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一個動量指標，它比較股票在價格上漲的日子裏的走強與價格下跌的日子的走強。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的數據，當相對強弱指數高於70時，資產通常被視爲超買。
Here's the latest list of major overbought players in this sector.
以下是該行業主要超買參與者的最新名單。
Verona Pharma PLC – ADR (NASDAQ:VRNA)
維羅納製藥有限公司 — ADR（納斯達克股票代碼：VRNA）
- Verona Pharma will report its financial results for the second quarter on Thursday, Aug. 8. The company's stock gained around 46% over the past month and has a 52-week high of $23.72.
- RSI Value: 71.29
- VRNA Price Action: Shares of Verona Pharma fell 0.5% to close at $22.61 on Monday.
- 維羅納製藥將於8月8日星期四公佈其第二季度的財務業績。該公司的股票在過去一個月中上漲了約46％，創下52周高點23.72美元。
- RSI 值：71.29
- VRNA價格走勢：週一，維羅納製藥公司股價下跌0.5％，收於22.61美元。
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)
Catalyst 製藥公司（納斯達克股票代碼：CPRX）
- On July 24, Catalyst Pharmaceuticals entered into an exclusive license, supply and commercialization agreement with Kye Pharmaceuticals for AGAMREE in Canada. "We are pleased to enter into this agreement with Kye Pharmaceuticals for AGAMREE, marking a pivotal milestone in our strategic initiative to expand the product's footprint in North America. This collaboration leverages our combined expertise, fortifies our alliance by licensing our second therapeutic rare disease product for Canada, and demonstrates our sustained commitment to patient care," stated Richard J. Daly, CEO and President of Catalyst. The company's stock gained around 11% over the past month and has a 52-week high of $17.99.
- RSI Value: 70.99
- CPRX Price Action: Shares of Catalyst Pharmaceuticals fell 0.6% to close at $17.48 on Monday.
- 7月24日，Catalyst Pharmicals與Kye Pharmicals簽訂了加拿大AGAMREE的獨家許可、供應和商業化協議。“我們很高興與Kye Pharmicals就AGAMREE簽訂這項協議，這標誌着我們擴大該產品在北美的足跡的戰略計劃中的一個關鍵里程碑。Catalyst首席執行官兼總裁理查德·戴利表示，這種合作利用了我們的綜合專業知識，通過向加拿大許可我們的第二款治療性罕見病產品來鞏固我們的聯盟，並表明了我們對患者護理的持續承諾。該公司的股票在過去一個月中上漲了約11％，創下52周高點17.99美元。
- RSI 值：70.99
- CPRX價格走勢：週一，Catalyst Pharmicals的股價下跌0.6％，收於17.48美元。
Viridian Therapeutics Inc (NASDAQ:VRDN)
Viridian Therapeutics公司（納斯達克股票代碼：VRDN）
- On July 29, Wedbush maintained an Outperform rating on the stock and reiterated its price target of $42. The company's stock gained around 31% over the past month and has a 52-week high of $24.18.
- RSI Value: 73.86
- VRDN Price Action: Shares of Viridian Therapeutics gained 3.8% to close at $17.29 on Monday.
- 7月29日，Wedbush維持該股跑贏大盤的評級，並重申了其42美元的目標股價。該公司的股票在過去一個月中上漲了約31％，創下52周高點24.18美元。
- RSI 值：73.86
- VRDN價格走勢：週一，Viridian Therapeutics的股價上漲3.8％，收於17.29美元。
- Roblox, Morgan Stanley And 2 Other Stocks Insiders Are Selling
- Roblox、摩根士丹利和其他兩隻股票內部人士正在拋售